WO2012000971A3 - Zusammensetzungen mit hohem wirkstoffanteil an einer mischung aus chondroitinsulfat und glucosamin - Google Patents

Zusammensetzungen mit hohem wirkstoffanteil an einer mischung aus chondroitinsulfat und glucosamin Download PDF

Info

Publication number
WO2012000971A3
WO2012000971A3 PCT/EP2011/060782 EP2011060782W WO2012000971A3 WO 2012000971 A3 WO2012000971 A3 WO 2012000971A3 EP 2011060782 W EP2011060782 W EP 2011060782W WO 2012000971 A3 WO2012000971 A3 WO 2012000971A3
Authority
WO
WIPO (PCT)
Prior art keywords
weight
glucosamine
mixture
compositions
chondroitin sulphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/060782
Other languages
English (en)
French (fr)
Other versions
WO2012000971A2 (de
Inventor
Simon Ensslin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mepha GmbH
Original Assignee
Mepha GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mepha GmbH filed Critical Mepha GmbH
Priority to AU2011273595A priority Critical patent/AU2011273595B2/en
Priority to EP11737910.7A priority patent/EP2588087A2/de
Priority to EA201390033A priority patent/EA025130B1/ru
Publication of WO2012000971A2 publication Critical patent/WO2012000971A2/de
Publication of WO2012000971A3 publication Critical patent/WO2012000971A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft eine Zusammensetzung enthaltend: a) mindestens 70 Gew.-% wenigstens einer pharmazeutisch aktiven Substanz, die eine Mischung aus Chondroitinsulfat und Glucosamin oder deren pharmazeutisch akzeptablen Salzen ist; b) 5 bis 25 Gew.-% wenigstens eines Bindemittels, wobei mindestens 30 Gew.-% des Bindemittels eine Partikelgrösse kleiner 70 μm aufweist; c) 0,1 bis 0,75 Gew.-% wenigstens eines Füllstoffes, wobei mindestens 90 Gew.-% des Füllstoffes eine Partikelgrösse kleiner 1,5 μm aufweist; und d) optional weitere Zusatzstoffe, wobei der Gesamtanteil an Bestandteilen in der Zusammensetzung 100 Gew.-% ergibt sowie eine orale Darreichungsform enthaltend die Zusammensetzung.
PCT/EP2011/060782 2010-06-29 2011-06-28 Zusammensetzungen mit hohem wirkstoffanteil an pharmazeutisch aktiven substanzen Ceased WO2012000971A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2011273595A AU2011273595B2 (en) 2010-06-29 2011-06-28 Compositions with a high active ingredient fraction of a mixture of chondroitin sulphate and glucosamine
EP11737910.7A EP2588087A2 (de) 2010-06-29 2011-06-28 Zusammensetzungen mit hohem wirkstoffanteil an einer mischung aus chondroitinsulfat und glucosamin
EA201390033A EA025130B1 (ru) 2010-06-29 2011-06-28 Композиции с высокой долей хондроитинсульфата и глюкозамина

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH01050/10 2010-06-29
CH01050/10A CH703348A1 (de) 2010-06-29 2010-06-29 Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.

Publications (2)

Publication Number Publication Date
WO2012000971A2 WO2012000971A2 (de) 2012-01-05
WO2012000971A3 true WO2012000971A3 (de) 2012-04-05

Family

ID=44629170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/060782 Ceased WO2012000971A2 (de) 2010-06-29 2011-06-28 Zusammensetzungen mit hohem wirkstoffanteil an pharmazeutisch aktiven substanzen

Country Status (5)

Country Link
EP (1) EP2588087A2 (de)
AU (1) AU2011273595B2 (de)
CH (1) CH703348A1 (de)
EA (1) EA025130B1 (de)
WO (1) WO2012000971A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108902987A (zh) * 2018-06-19 2018-11-30 北京中健天行医药科技有限公司 乳矿物盐氨糖软骨素维d胶囊

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767899B1 (en) * 2000-08-29 2004-07-27 Leiner Health Services Corp. Composition and method for treatment of conditions having an inflammatory component
US7056531B1 (en) * 2000-05-04 2006-06-06 Nature's Way Products, Inc. Sustained release compositions for orally administered substances and methods
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
BRPI0612802A2 (pt) * 2005-07-07 2010-11-30 Farnam Co Inc composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis
WO2008134005A1 (en) * 2007-04-24 2008-11-06 Jrs Pharma Lp Co-processing of active pharmaceutical/nutraceutical ingredients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056531B1 (en) * 2000-05-04 2006-06-06 Nature's Way Products, Inc. Sustained release compositions for orally administered substances and methods
US6767899B1 (en) * 2000-08-29 2004-07-27 Leiner Health Services Corp. Composition and method for treatment of conditions having an inflammatory component
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAUER K.H., FRÖMMING K-H., FÜHRER C.: "Pharmazeutische Technologie", 1997, GUSTAV FISCHER VERLAG, Germany, ISBN: 3-437-25630-0, pages: 314 - 314, XP002665472 *

Also Published As

Publication number Publication date
CH703348A1 (de) 2011-12-30
EA025130B1 (ru) 2016-11-30
AU2011273595B2 (en) 2015-08-20
WO2012000971A2 (de) 2012-01-05
AU2011273595A1 (en) 2013-02-14
EA201390033A1 (ru) 2013-06-28
EP2588087A2 (de) 2013-05-08

Similar Documents

Publication Publication Date Title
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
WO2011163600A3 (en) Tacrolimus compositions for aerosol administration
WO2011106416A3 (en) Abuse-resistant formulations
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
WO2012056402A3 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
WO2008051291A3 (en) Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
WO2012001074A3 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
MX2010003923A (es) Formulacion farmaceutica de valsartan.
MX354102B (es) Derivados de bencimidazol-prolina.
WO2010093944A3 (en) Delayed release, oral dosage compositions that contain amorphous cddo-me
WO2008140507A3 (en) Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
BR112013026965A2 (pt) método para inibir micro-organismos prejudiciais e composição formadora de barreira para os mesmos
EP3329965A3 (de) Dosierung von anti-alpha4beta7-antikörper
NZ707551A (en) Prostacyclin compositions and methods for using the same
WO2012021715A3 (en) Stable formulations of linaclotide
NZ589017A (en) Solid pharmaceutical formulation with delayed release
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
WO2010038091A3 (en) Compositions comrrising amlodipine and bisoprolol
EP2571486A4 (de) Trockenpulverinhalationszusammensetzung
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2008102321A3 (en) Oral polyphosphate compositions
MY177591A (en) Nk1 receptor antagonist composition
WO2008056375A3 (en) Pharmaceutical formulations comprising valsartan
WO2013085897A3 (en) A method for reducing agglomeration in gypsum plaster or filling compositions comprising cellulose ether
MX2008001645A (es) Composiciones de fexofendina en suspension farmaceutica oral.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11737910

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 223839

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011737910

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011737910

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201390033

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2011273595

Country of ref document: AU

Date of ref document: 20110628

Kind code of ref document: A